Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities
Net loss	$ (154,626)	$ (40,540)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	3,623	3,298
Non-cash operating lease cost	1,304	987
Non-cash interest expense and amortization of debt issuance costs	776	2,906
Payment on notes attributed to accreted interest related to the debt discounts		(6,788)
Acquired in-process research and development		12,271
Impairment of in-process research and development	11,900
Stock-based compensation	18,282	20,792
Loss on debt extinguishment, net	40	5,262
Loss (gain) on derivative liabilities	1,280	(7,500)
Loss (gain) on marketable investments	13,683	(68,534)
Loss on equity method investments	368	131
DIP Facility upfront lender fees and debt issuance costs	2,725
DIP Facility Exit Fee	5,250	0
Increase (decrease) on contingent consideration	3,800	(2,100)
Deferred income taxes	(353)	1,086
Current income taxes	11,847
Changes in operating assets and liabilities, excluding effect of acquisitions:
Accounts receivable	(2,047)	(5,982)
Inventory	(1,333)	(5,979)
Accrued payroll	(2,541)	3,949
Prepaid expenses, deposits and other assets	131	(1,640)
Accounts payable	18,233	(2,571)
Accrued expenses and other liabilities	16,357	9,122
Deferred revenue	563	(1,709)
Accrued legal settlements	1,797
Other	(518)	179
Net cash used for operating activities	(49,459)	(83,360)
Investing activities
Purchases of property and equipment	(86)	(2,593)
Acquisition consideration paid in cash, net of cash acquired		(4,527)
Proceeds received from exit of FortuneBio investment	1,770
Net cash provided by (used for) for investing activities	1,684	(13,664)
Financing activities
Proceeds from DIP Facility, net of lender fees and debt issuance costs	27,275
Proceeds from other short-term debt, net of issuance costs	4,907	57,121
Proceeds from issuance of Scilex convertible debentures	9,600
Proceeds from exercises of stock options and warrants		132
Repayments of debt and other obligations	(3,557)	(48,316)
Net cash provided by financing activities	61,196	173,369
Net change in cash, cash equivalents and restricted cash	13,421	76,345
Net effect of exchange rate changes on cash	600	(1,104)
Cash, cash equivalents and restricted cash at beginning of period	23,634	36,665
Cash, cash equivalents and restricted cash at end of period	37,655	111,906
Cash paid during the period for:
Interest		116
Income taxes		53
Supplemental disclosures of non-cash investing and financing activities:
Stock dividends	(14,282)
DIP Facility Exit Fee incurred but not paid	5,250
Virex Health acquisition consideration paid in equity		4,435
Bridge Loan settlement through ATM proceeds	6,166
Property and equipment costs incurred but not paid	5,301	457
Virex Health, Inc
Investing activities
Acquisition consideration paid in cash, net of cash acquired		(6,544)
Public Offering Of Common Stock And Warrants 2019
Financing activities
Proceeds from equity offerings, net of issuance costs	$ 22,971	$ 164,432